Ignite Creation Date:
2024-05-06 @ 1:37 PM
Last Modification Date:
2024-10-26 @ 1:17 PM
Study NCT ID:
NCT04077099
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-03-06
First Post:
2019-08-13
Brief Title:
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor MET-Altered Advanced Non-Small Cell Lung Cancer
Sponsor:
Regeneron Pharmaceuticals
Organization:
Regeneron Pharmaceuticals
Study Overview
Official Title:
A Phase 12 Study of REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate REGN5093 for the treatment of Non-Small Cell Lung Cancer NSCLC with MET alteration The main purpose of this study is to determine the safety tolerability and effectiveness of REGN5093
The study has two phases The main goal of Phase 1 is to determine a safe doses of REGN5093 The main goal of phase 2 of the study is to use the REGN5093 drug doses found in Phase 1 to see how well REGN5093 works to shrink tumors
The study is looking at several other research questions including
Side effects that may be experienced by people taking REGN5093
How REGN5093 works in the body
How much REGN5093 is present in the blood
To see if REGN5093 works to reduce or delay the progression of cancer
How long it takes REGN5093 to work in the body
The study has two phases The main goal of Phase 1 is to determine a safe doses of REGN5093 The main goal of phase 2 of the study is to use the REGN5093 drug doses found in Phase 1 to see how well REGN5093 works to shrink tumors
The study is looking at several other research questions including
Side effects that may be experienced by people taking REGN5093
How REGN5093 works in the body
How much REGN5093 is present in the blood
To see if REGN5093 works to reduce or delay the progression of cancer
How long it takes REGN5093 to work in the body
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2019-001908-38 | EUDRACT_NUMBER | None | None |